When it comes to weight loss, Arena Pharmaceuticals is throwing in the towel.

The small San Diego biotech company had once expected its anti-obesity drug, Belviq, to be a blockbuster — after all, more than one-third of Americans are obese. But the market wasn’t interested, and sales never lived up to expectations — leading the company to slash its employee count by 120, nearly three-quarters of its workforce.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for our biotech newsletter, The Readout

Get our guide to what's new in biotech delivered each morning.

Recommended Stories